Business
EyePoint Pharmaceuticals Announces Presentations at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting
WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and
About this update from Eyepoint, Inc.
[{"type":"text","content":"WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that four abstracts featuring YUTIQ® and DEXYCU® have been selected for presentation at the upcoming American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting, taking place November 13-15, 2020.\n Details for the AAO presentations are as follows: Paper Presentation Second Phase 3 trial of YUTIQ shows durable 36-month anti-inflammatory activity for difficult to treat ocular disease Title: FAi Insert Treatment for Noninfectious Posterior Uveitis: Three-Year Results of a Confirmatory TrialPresenter: Glenn J. Jaffe, M.D., Robert Machemer M. D. Distinguished Professor of Ophthalmology, Duke University School of MedicineSession: PA063Date and time: Available on demand Nov 14-15, 2020 Poster Presentations Investigator-sponsored study demonstrates patient preference of DEXYCU and a “minimum eye drop” regimen Title: The D3 Study: Drug Delivery vs. Drops—A Prospective Clinical Study Evaluating Dexycu vs. Prednisolone Acetate 1% in Controlling Postoperative Pain and Inflammation in Patients Undergoing Sequential Cataract SurgeryPresenter: John A. Hovanesian, M.D., Specialist in Cataract, Refractive, Cornea and Pterygium Surgery, Harvard Eye Associates Session: PO049Date and time: Available on demand Nov 14-15, 2020 Real-world data of DEXYCU highlights durable anti-inflammatory activity and results comparable to Phase 3 clinical trials Title: Dexamethasone Intraocular Suspension 9% After Cataract Surgery: Data From a Retrospective StudyPresenter: Robert J. Weinstock, M.D., Director of Cataract and Refractive Surgery, The Eye Institute of West Florida and the Weinstock Laser Eye CenterSession: PO050Date and time: Available on demand Nov 14-15, 2020 Real world data of DEXYCU shows strong anti-inflammatory efficacy with and without additional topical anti-inflammatory treatmentTitle: Outcomes With Dexamethasone Intraocular Suspension 9% and Concomitant Postoperative Anti-inflammatory MedicationsPresenter: Cynthia Matossian, M.D., Founder and Chief Executive Officer, Matossian Eye AssociatesSession: PO051Date and time: Available on demand Nov 14-15, 2020 About EyePoint PharmaceuticalsEyePoint Pharmaceuticals, Inc. (www.eye...